<DOC>
	<DOCNO>NCT02659514</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability poziotinib patient HER2-positive metastatic breast cancer receive least 2 prior HER2-directed treatment regimen .</brief_summary>
	<brief_title>Study Poziotinib Patients With HER2-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>This phase 2 , open-label , multicenter study evaluate efficacy tolerability poziotinib approximately 70 patient HER2-positive metastatic breast cancer receive least 2 prior HER2-directed treatment regimen . Each treatment cycle 21 day duration . During 21-day cycle , patient eligible participation receive poziotinib orally daily 14 day , follow 7 treatment-free rest day . All treat patient follow disease progression , death , intolerable adverse event maximum 24 month whichever come early .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Histopathologically confirm metastatic breast cancer 2 . Confirmed HER2 overexpression geneamplified tumor 3 . At least 2 prior HER2directed therapy regimens metastatic breast cancer , include trastuzumab TDM1 . 4 . Patient least 18 year age . 5 . Patient adequate hematologic , hepatic , renal function 6 . At least one measurable lesion 1 . Previous treatment poziotinib prior study participation . 2 . Brain metastasis untreated , symptomatic , require therapy control symptom , well history radiation , surgery , therapy , include steroid , control symptom brain metastasis within 1 month ( 30 day ) enrollment . 3 . Anticancer chemotherapy , biologics , immunotherapy , radiotherapy , investigational treatment within 30 day , except hormone therapy , could give 7 day prior first dose poziotinib . 4 . History congestive heart failure ( CHF ) Class III/IV accord New York Heart Association ( NYHA ) Functional Classification serious cardiac arrhythmia require treatment . 5 . Patient cardiac ejection fraction &lt; 50 % 6 . Patient history malignancy within last 5 year 7 . Unable take drug orally 8 . Patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Poziotinib</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>Pan-HER inhibitor</keyword>
</DOC>